Skip to content
2000
Volume 28, Issue 9
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Background

Wuling capsule is a traditional Chinese medicine composed of four herbals. It has been widely used to treat chronic active hepatitis and has shown significant efficacy in hyperlipidemia. However, the treatment of NAFLD disease has not been studied in depth.

Methods

Firstly, the potential bioactive compounds in Wuling capsules were identified by TCMSP (https://old.tcmsp-e.com/tcmsp.php). Secondly, the pathway and GO function were analyzed by using the DAVID database (https://david.ncifcrf.gov/). Then, the molecular docking techniques were used to confirm the accuracy of binding between key targets and components. Furthermore, the experimental pharmacology validation was conducted using RT-qPCR and WB of the NAFLD model.

Results

A total of 138 active compounds and 40 common potential targets associated with NAFLD were identified through network pharmacology. The pathway and functional enrichment analysis showed that the Wuling capsule was associated with the PI3K-AKT and HIF-1α signaling pathways. experiments showed that the Wuling capsule could reduce IL-6, TNF-α, and HIF-1α proteins and up-regulate STAT3 and VEGFA levels ( < 0.05), thus alleviating liver inflammation.

Conclusions

With the support of network pharmacology and animal experiments, the study preliminarily investigated the effect of the Wuling capsule on liver inflammation by regulating the HIF-1α signaling pathway, thereby protecting liver function and treating NAFLD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073311193240529080100
2024-06-14
2025-09-24

  • From This Site

    /content/journals/cchts/10.2174/0113862073311193240529080100
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WongV.W.S. ChuW.C.W. WongG.L.H. ChanR.S.M. ChimA.M.L. OngA. YeungD.K.W. YiuK.K.L. ChuS.H.T. WooJ. ChanF.K.L. ChanH.L.Y. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography.Gut201261340941510.1136/gutjnl‑2011‑300342 21846782
     [Google Scholar]
  2. TargherG. TilgH. ByrneC.D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.Lancet Gastroenterol. Hepatol.20216757858810.1016/S2468‑1253(21)00020‑0 33961787
     [Google Scholar]
  3. ZhangS.S. Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease. J.Clinic. Hepatobiliary dis.,2017331222702274
     [Google Scholar]
  4. WangC.H. LiuH.M. ChangZ.Y. HuangT.H. LeeT.Y. Losartan Prevents Hepatic Steatosis and Macrophage Polarization by Inhibiting HIF-1α in a Murine Model of NAFLD.Int. J. Mol. Sci.20212215784110.3390/ijms22157841
     [Google Scholar]
  5. WangX. de Carvalho RibeiroM. Iracheta-VellveA. LoweP. AmbadeA. SatishchandranA. BukongT. CatalanoD. KodysK. SzaboG. Macrophage‐Specific Hypoxia‐Inducible Factor‐1α Contributes to Impaired Autophagic Flux in Nonalcoholic Steatohepatitis.Hepatology201969254556310.1002/hep.30215 30102772
     [Google Scholar]
  6. HungT.C. ZhaoN. HuangC. LiuS. LiuT. HuangW. XuX. JiZ.L. YangS. Exploring the mechanism of PingTang No.5 capsule on nonalcoholic fatty liver disease through network pharmacology and experimental validation.Biomed. Pharmacother.202113811140810.1016/j.biopha.2021.111408 33684693
     [Google Scholar]
  7. DaiX. FengJ. ChenY. HuangS. ShiX. LiuX. SunY. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives.Chin. Med.20211616810.1186/s13020‑021‑00469‑4 34344394
     [Google Scholar]
  8. WuJ. PengY.Z. The effect of Feiliganning capsule in treating non-alcoholic simple fatty liver.Practi. Clini. Med.201819646
     [Google Scholar]
  9. JiangY.Y. LinJ. DongP.L. WangX.B. Clinical study of Rhubarb Lidan capsule in treatment of non-alcoholic steatohepatitis.Chin. J. Integr. Med.20173705539542
     [Google Scholar]
  10. LinY. WangX. YeR. HuW. SunS. JiaoH. SongX. YuanZ. ZhengY. ZhengG. HeJ.C. Efficacy and safety of Wuling capsule, a single herbal formula, in Chinese subjects with insomnia: A multicenter, randomized, double-blind, placebo-controlled trial.J. Ethnopharmacol.2013145132032710.1016/j.jep.2012.11.009 23178661
     [Google Scholar]
  11. WangH. ChenH. GaoY. WangS. WangX. TangX. FangW. ShiX. YaoJ. ChenQ. The effect of wuling capsule on depression in Type 2 diabetic patients.Biosci. Rep.2020402BSR2019126010.1042/BSR20191260 31894843
     [Google Scholar]
  12. HuY.W. WangS.C. liu, M.Y., Wang, J.Q., Wang, Y.M.Effects of Wuling Capsule on collagen and matrix metalloproteinases in liver fibrosis rats.Liver20101504276280 [J].
     [Google Scholar]
  13. ChenL. CaoF. SongZ.X. KongX. MaM.G. Comparison of protective effect of Wuling capsule on hepatic fibrosis induced by carbon tetrachloride in rats before and after process optimization.Journal of Naval Medical University2022431214291436 [J].
     [Google Scholar]
  14. Tian, Y Effect of Entecavir combined with Fuzhenghuayu capsule on liver cirrhosis of compensatory hepatitis B and its influence on liver function and serum liver fibrosis indexes. Clinic.Med. Res. Pract.201946101103
     [Google Scholar]
  15. QuX.H. WangS.C. HuangP.J. TianW.B. Orthogonal test to investigate the effect of Five Spirit Capsules dispensing on mice with chronic liver injury.Chin. Med.20113302232235
     [Google Scholar]
  16. LiN. EenS.J. ZhouR. SongZ.X. lLiu, Y.R., Tang, Z.S., Zhou, J.P., Cao, Z.J.Discussion on the mechanism of anti-hepatic fibrosis of Wuling capsule based on network pharmacology and animal experiments.Chinese J. Tradit. Chinese Med.2023481953655376
     [Google Scholar]
  17. ChenX.L. ChenS.N. ShiY. LiY.C. Analysis of the pharmacodynamic constituents of Wuling capsule against hepatocellular injury by HPLC method.J. Fourth Military Med. Uni.20041311681171
     [Google Scholar]
  18. HuY.W. WangS.C. HuangP.M.J. TainW.B. Withdrawal of drugs and analysis of formulae to analyze the anti-hepatic fibrosis effects of Wu Ling Capsule and its constituent components.Chinese J. Exper. Formul.20101605163167
     [Google Scholar]
  19. SunJ. SunG. MengX. WangH. LuoY. QinM. MaB. WangM. CaiD. GuoP. SunX. Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.PLoS One201385e6452610.1371/journal.pone.0064526 23724057
     [Google Scholar]
  20. KaixuanZ. DongZ. HuiweiB. LijingL.I. Network pharmacology and molecular docking study on the effect of Kaempferol in treatment of metabolic associated fatty liver disease.J. Tradit. Chin. Med.2022425788794 36083487
     [Google Scholar]
  21. Jordão CandidoC. Silva FigueiredoP. Del Ciampo SilvaR. Candeloro PortugalL. Augusto dos Santos JaquesJ. Alves de AlmeidaJ. de Barros PenteadoB. Albuquerque DiasD. MarcelinoG. PottA. Avellaneda GuimarãesR.C. Aiko HianeP. Protective effect of α-linolenic acid on non-alcoholic hepatic steatosis and interleukin-6 and -10 in wistar rats.Nutrients2019121910.3390/nu12010009 31861497
     [Google Scholar]
  22. FengS. DaiZ. LiuA.B. HuangJ. NarsipurN. GuoG. KongB. ReuhlK. LuW. LuoZ. YangC.S. Intake of stigmasterol and β-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet.Biochim. Biophys. Acta Mol. Cell Biol. Lipids20181863101274128410.1016/j.bbalip.2018.08.004 30305244
     [Google Scholar]
  23. LiQ.Q. XiongJ.H. WenY.Q. YangH.S. LiJ.D. FangM. LiuY.W. Protective effect of tanshinone IIA on acute liver injury induced by CCl4 in mice. Chinese J. Clinic.Anat.20224006671676
     [Google Scholar]
  24. SunW.L. YangJ.W. DouH.Y. LiG.Q. LiX.Y. ShenL. JiH.F. Anti-inflammatory effect of luteolin is related to the changes in the gut microbiota and contributes to preventing the progression from simple steatosis to nonalcoholic steatohepatitis.Bioorg. Chem.202111210496610.1016/j.bioorg.2021.104966 33991837
     [Google Scholar]
  25. ZhangK.X. QianX.J. ZhengW. CaiM.C. MaY. ZhangD.Z. YuS.C. MengQ.G. JinY.S. Synthesis and in vitro anti-HCV and antitumor evaluation of schisandronic acid derivatives.Med. Chem.202117997498210.2174/1573406416999200818150053 32819233
     [Google Scholar]
  26. HolznerL.M.W. MurrayA.J. Hypoxia-inducible factors as key players in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Front. Med.2021875326810.3389/fmed.2021.753268 34692739
     [Google Scholar]
  27. ZhaoY. MaD.X. WangH.G. LiM.Z. TalukderM. WangH.R. LiJ.L. Lycopene prevents DEHP-induced liver lipid metabolism disorder by inhibiting the HIF-1α-induced PPARα/PPARγ/FXR/LXR system.J. Agric. Food Chem.20206841114681147910.1021/acs.jafc.0c05077 32962341
     [Google Scholar]
  28. WangR. LiD. QiW.J. SunJ.J. ZhangZ.T. ZhaiM.H. Expression and clinical significance of HIF-1α and Th17/Treg in peripheral blood of patients with non-alcoholic fatty liver disease.Clin J Med Off.201947016465 [J].
     [Google Scholar]
  29. MesarwiO.A. MoyaE.A. ZhenX. GautaneM. ZhaoH. Wegbrans GiróP. AlshebliM. McCarleyK.E. BreenE.C. MalhotraA. Hepatocyte HIF-1 and intermittent hypoxia independently impact liver fibrosis in murine nonalcoholic fatty liver disease.Am. J. Respir. Cell Mol. Biol.202165439040210.1165/rcmb.2020‑0492OC 34003729
     [Google Scholar]
  30. HeY. WangH. LinS. ChenT. ChangD. SunY. WangC. LiuY. LuY. SongJ. LiS. XuW. LinY. ZhengY. ZhouX. HuangQ. HuangM. Advanced effect of curcumin and resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K/AKT/mTOR and HIF-1/VEGF cascade.Biomed. Pharmacother.202316511527910.1016/j.biopha.2023.115279 37544281
     [Google Scholar]
  31. YinG. LiangH. SunW. ZhangS. FengY. LiangP. ChenS. LiuX. PanW. ZhangF. Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo.Front. Pharmacol.202213101674510.3389/fphar.2022.1016745 36506575
     [Google Scholar]
  32. TilgH. HotamisligilG.S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance.Gastroenterology2006131393494510.1053/j.gastro.2006.05.054 16952562
     [Google Scholar]
  33. ZhangZ. ZhangY. GaoM. CuiX. YangY. van DuijnB. WangM. HuY. WangC. XiongY. Steamed Panax notoginseng Attenuates Anemia in Mice With Blood Deficiency Syndrome via Regulating Hematopoietic Factors and JAK-STAT Pathway.Front. Pharmacol.20192019101578 32038252
     [Google Scholar]
  34. ShrikiA. LantonT. SonnenblickA. Levkovitch-SianyO. EidelshteinD. AbramovitchR. RosenbergN. PappoO. ElgavishS. NevoY. SafadiR. PeledA. Rose-JohnS. GalunE. AxelrodJ.H. Multiple Roles of IL6 in Hepatic Injury, Steatosis, and Senescence Aggregate to Suppress Tumorigenesis.Cancer Res.202181184766477710.1158/0008‑5472.CAN‑21‑0321 34117031
     [Google Scholar]
  35. ZhuJ. ZhouM. ZhaoX. MuM. ChengM. Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1/STAT3/BAX signaling.Food Funct.20189126298630610.1039/C8FO01227J 30411754
     [Google Scholar]
  36. BraileM. MarcellaS. CristinzianoL. GaldieroM.R. ModestinoL. FerraraA.L. VarricchiG. MaroneG. LoffredoS. VEGF-A in Cardiomyocytes and Heart Diseases.Int. J. Mol. Sci.20202115529410.3390/ijms21155294 32722551
     [Google Scholar]
  37. DrygalskiK. SiewkoK. ChomentowskiA. OdrzygóźdźC. ZalewskaA. KrętowskiA. MaciejczykM. Phloroglucinol strengthens the antioxidant barrier and reduces oxidative/nitrosative stress in Nonalcoholic Fatty Liver Disease (NAFLD).Oxid. Med. Cell. Longev.2021202111810.1155/2021/8872702 33510844
     [Google Scholar]
  38. ZhengY. HuangC. ZhaoL. ChenY. LiuF. Regulation of decorin by ursolic acid protects against non-alcoholic steatohepatitis.Biomed. Pharmacother.202114311216610.1016/j.biopha.2021.112166 34560554
     [Google Scholar]
  39. FogliaB. SuttiS. PediciniD. CannitoS. BoccaC. MaggioraM. BevacquaM.R. RossoC. BugianesiE. AlbanoE. NovoE. ParolaM. OncostatinM. A profibrogenic mediator overexpressed in non-alcoholic fatty liver disease, stimulates migration of hepatic myofibroblasts.Cells2019912810.3390/cells9010028 31861914
     [Google Scholar]
/content/journals/cchts/10.2174/0113862073311193240529080100
Loading
The Integration of Systematic Pharmacology and Experimental Validation to Explain the Mechanism of Action of Wuling Capsule in the Treatment of NAFLD
Comb Chem High Throughput Screen 28, 1604 (2025); https://doi.org/10.2174/0113862073311193240529080100
/content/journals/cchts/10.2174/0113862073311193240529080100
/content/journals/cchts/10.2174/0113862073311193240529080100
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): HIF-1α pathway; in vivo validation; molecular docking; NAFLD; network pharmacology; Wuling capsule

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test